GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Cash-to-Debt

Biote (BTMD) Cash-to-Debt : 0.36 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biote Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biote's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.36.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biote couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Biote's Cash-to-Debt or its related term are showing as below:

BTMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36   Med: 0.66   Max: 0.78
Current: 0.36

During the past 6 years, Biote's highest Cash to Debt Ratio was 0.78. The lowest was 0.36. And the median was 0.66.

BTMD's Cash-to-Debt is ranked worse than
64.16% of 664 companies
in the Healthcare Providers & Services industry
Industry Median: 0.77 vs BTMD: 0.36

Biote Cash-to-Debt Historical Data

The historical data trend for Biote's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biote Cash-to-Debt Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial 0.41 0.72 0.66 0.78 0.36

Biote Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.69 0.22 0.31 0.36

Competitive Comparison of Biote's Cash-to-Debt

For the Medical Care Facilities subindustry, Biote's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biote's Cash-to-Debt Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Biote's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biote's Cash-to-Debt falls into.


;
;

Biote Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biote's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Biote's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biote  (NAS:BTMD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Biote Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biote's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biote Business Description

Traded in Other Exchanges
N/A
Address
1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
Executives
Stephen Mark Cone director C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Guines Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Marc D Beer director C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Andrew R Heyer director, officer: President and Director 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Mary Elizabeth Conlon officer: General Counsel C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Daniel M. Friedberg 10 percent owner C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
Anil K Shrivastava 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
325 Capital Llc 10 percent owner 757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar officer: Chief Commercial Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Samar Jagat Kamdar officer: Chief Financial Officer 7042 CORONADO AVE., DALLAS TX 75214
Roystone Capital Management Lp 10 percent owner 780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Debra L Morris director 11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Roystone Capital Holdings Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Teresa Sue Weber director, officer: Chief Executive Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038